LAWRENCEVILLE, N.J.,
Sept. 3, 2015 /PRNewswire/
-- Celsion Corporation (NASDAQ: CLSN), a leading oncology drug
development company, today announced that Michael H. Tardugno, Celsion's Chairman,
President and Chief Executive Officer, will present at the Rodman
& Renshaw 17th Annual Global Investment Conference on
Wednesday, September 9, 2015 at
11:15 a.m. Eastern Time. The
conference will take place from September
8-10, 2015 at the St. Regis Hotel in New York City. A
copy of the presentation will be available on Celsion's website at
investor.celsion.com/events.cfm.
About Celsion Corporation
Celsion is a fully-integrated oncology company focused on
developing a portfolio of innovative cancer treatments, including
directed chemotherapies, immunotherapies and RNA- or DNA-based
therapies. The Company's lead program is ThermoDox®, a proprietary
heat-activated liposomal encapsulation of doxorubicin, currently in
Phase III development for the treatment of primary liver cancer and
in Phase II development for the treatment of recurrent chest wall
breast cancer. The pipeline also includes GEN-1, a DNA-based
immunotherapy for the localized treatment of ovarian and brain
cancers. Celsion has two platform technologies for the
development of novel nucleic acid-based immunotherapies and other
anti-cancer DNA or RNA therapies, including TheraPlas™ and
TheraSilence™. For more information on Celsion, visit our
website: http://www.celsion.com.
Celsion wishes to inform readers that forward-looking
statements in this release are made pursuant to the "safe harbor"
provisions of the Private Securities Litigation Reform Act of
1995. Readers are cautioned that such forward-looking
statements involve risks and uncertainties including, without
limitation, unforeseen changes in the course of research and
development activities and in clinical trials; FDA and regulatory
uncertainties and risks; the significant expense, time, and risk of
failure of conducting clinical trials; the need for Celsion to
evaluate its future development plans; possible acquisitions or
licenses of other technologies, assets or businesses; possible
actions by customers, suppliers, competitors, regulatory
authorities; and other risks detailed from time to time in the
Celsion's periodic reports and prospectuses filed with the
Securities and Exchange Commission. Celsion assumes no
obligation to update or supplement forward-looking statements that
become untrue because of subsequent events, new information or
otherwise.
Celsion Investor Contact
Jeffrey W. Church
Sr. Vice President and CFO
609-482-2455
jchurch@celsion.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/celsion-to-present-at-the-rodman--renshaw-17th-annual-global-investment-conference-300137466.html
SOURCE Celsion Corporation